192 related articles for article (PubMed ID: 12231043)
1. Radiation and hormonal therapy for locally advanced and clinically localized prostate cancer.
D'Amico AV
Urology; 2002 Sep; 60(3 Suppl 1):32-7; discussion 37-8. PubMed ID: 12231043
[TBL] [Abstract][Full Text] [Related]
2. Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial.
Denham JW; Steigler A; Lamb DS; Joseph D; Turner S; Matthews J; Atkinson C; North J; Christie D; Spry NA; Tai KH; Wynne C; D'Este C
Lancet Oncol; 2011 May; 12(5):451-9. PubMed ID: 21440505
[TBL] [Abstract][Full Text] [Related]
3. Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate.
Lawton CA; Winter K; Murray K; Machtay M; Mesic JB; Hanks GE; Coughlin CT; Pilepich MV
Int J Radiat Oncol Biol Phys; 2001 Mar; 49(4):937-46. PubMed ID: 11240234
[TBL] [Abstract][Full Text] [Related]
4. The indications, rationale, and results of neoadjuvant androgen deprivation in the treatment of prostatic cancer: Memorial Sloan-Kettering Cancer Center results.
Fair WR; Cookson MS; Stroumbakis N; Cohen D; Aprikian AG; Wang Y; Russo P; Soloway SM; Sogani P; Sheinfeld J; Herr H; Dalgabni G; Begg CB; Heston WD; Reuter VE
Urology; 1997 Mar; 49(3A Suppl):46-55. PubMed ID: 9123736
[TBL] [Abstract][Full Text] [Related]
5. Report of a multicenter Canadian phase III randomized trial of 3 months vs. 8 months neoadjuvant androgen deprivation before standard-dose radiotherapy for clinically localized prostate cancer.
Crook J; Ludgate C; Malone S; Lim J; Perry G; Eapen L; Bowen J; Robertson S; Lockwood G
Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):15-23. PubMed ID: 15337535
[TBL] [Abstract][Full Text] [Related]
6. The need for androgen deprivation therapy in patients with intermediate-risk prostate cancer treated with dose-escalated external beam radiation therapy.
Dong Y; Ruth KJ; Churilla TM; Viterbo R; Sobczak ML; Smaldone MC; Chen DY; Uzzo RG; Hallman MH; Horwitz EM
Can J Urol; 2017 Feb; 24(1):8656-8662. PubMed ID: 28263132
[TBL] [Abstract][Full Text] [Related]
7. National practice patterns and time trends in androgen ablation for localized prostate cancer.
Cooperberg MR; Grossfeld GD; Lubeck DP; Carroll PR
J Natl Cancer Inst; 2003 Jul; 95(13):981-9. PubMed ID: 12837834
[TBL] [Abstract][Full Text] [Related]
8. Long-term survival after radical prostatectomy versus external-beam radiotherapy for patients with high-risk prostate cancer.
Boorjian SA; Karnes RJ; Viterbo R; Rangel LJ; Bergstralh EJ; Horwitz EM; Blute ML; Buyyounouski MK
Cancer; 2011 Jul; 117(13):2883-91. PubMed ID: 21692049
[TBL] [Abstract][Full Text] [Related]
9. Stage T3 prostate cancer: a nonrandomized comparison between definitive irradiation and induction hormonal manipulation plus prostatectomy.
Corn BW; Valicenti RK; Mulholland SG; Hyslop T; Gomella L
Urology; 1998 May; 51(5):782-7. PubMed ID: 9610592
[TBL] [Abstract][Full Text] [Related]
10. Dose escalated external beam radiotherapy versus neoadjuvant androgen deprivation therapy and conventional dose external beam radiotherapy for clinically localized prostate cancer: do we need both?
Roach M
Strahlenther Onkol; 2007 Dec; 183 Spec No 2():26-8. PubMed ID: 18167004
[TBL] [Abstract][Full Text] [Related]
11. Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610.
Roach M; Bae K; Speight J; Wolkov HB; Rubin P; Lee RJ; Lawton C; Valicenti R; Grignon D; Pilepich MV
J Clin Oncol; 2008 Feb; 26(4):585-91. PubMed ID: 18172188
[TBL] [Abstract][Full Text] [Related]
12. Initial decline in hemoglobin during neoadjuvant hormonal therapy predicts for early prostate specific antigen failure following radiation and hormonal therapy for patients with intermediate and high-risk prostate cancer.
D'Amico AV; Saegaert T; Chen MH; Renshaw AA; George D; Oh W; Kantoff PW
Cancer; 2002 Jul; 95(2):275-80. PubMed ID: 12124826
[TBL] [Abstract][Full Text] [Related]
13. Undetectable prostate specific antigen at 6-12 months: a new marker for early success in hormonally treated patients after prostate brachytherapy.
Miller N; Smolkin ME; Bissonette E; Theodorescu D
Cancer; 2005 Jun; 103(12):2499-506. PubMed ID: 15852361
[TBL] [Abstract][Full Text] [Related]
14. Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial.
Fizazi K; Faivre L; Lesaunier F; Delva R; Gravis G; Rolland F; Priou F; Ferrero JM; Houede N; Mourey L; Theodore C; Krakowski I; Berdah JF; Baciuchka M; Laguerre B; Fléchon A; Ravaud A; Cojean-Zelek I; Oudard S; Labourey JL; Chinet-Charrot P; Legouffe E; Lagrange JL; Linassier C; Deplanque G; Beuzeboc P; Davin JL; Martin AL; Habibian M; Laplanche A; Culine S
Lancet Oncol; 2015 Jul; 16(7):787-94. PubMed ID: 26028518
[TBL] [Abstract][Full Text] [Related]
15. Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial.
Carrie C; Hasbini A; de Laroche G; Richaud P; Guerif S; Latorzeff I; Supiot S; Bosset M; Lagrange JL; Beckendorf V; Lesaunier F; Dubray B; Wagner JP; N'Guyen TD; Suchaud JP; Créhange G; Barbier N; Habibian M; Ferlay C; Fourneret P; Ruffion A; Dussart S
Lancet Oncol; 2016 Jun; 17(6):747-756. PubMed ID: 27160475
[TBL] [Abstract][Full Text] [Related]
16. Lack of Apparent Survival Benefit With Use of Androgen Deprivation Therapy in Patients With High-risk Prostate Cancer Receiving Combined External Beam Radiation Therapy and Brachytherapy.
Yang DD; Muralidhar V; Mahal BA; Nguyen PL; Devlin PM; King MT; Orio PF
Int J Radiat Oncol Biol Phys; 2018 Jan; 100(1):53-58. PubMed ID: 29254781
[TBL] [Abstract][Full Text] [Related]
17. High-dose radiation employing external beam radiotherapy and high-dose rate brachytherapy with and without neoadjuvant androgen deprivation for prostate cancer patients with intermediate- and high-risk features.
Vargas C; Martínez A; Galalae R; Demanes J; Harsolia A; Schour L; Nuernberg N; Gonzalez J
Prostate Cancer Prostatic Dis; 2006; 9(3):245-53. PubMed ID: 16786040
[TBL] [Abstract][Full Text] [Related]
18. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin.
Bolla M; Gonzalez D; Warde P; Dubois JB; Mirimanoff RO; Storme G; Bernier J; Kuten A; Sternberg C; Gil T; Collette L; Pierart M
N Engl J Med; 1997 Jul; 337(5):295-300. PubMed ID: 9233866
[TBL] [Abstract][Full Text] [Related]
19. Prostate-specific antigen screening trials and prostate cancer deaths: the androgen deprivation connection.
Haines IE; Gabor Miklos GL
J Natl Cancer Inst; 2013 Oct; 105(20):1534-9. PubMed ID: 24092918
[TBL] [Abstract][Full Text] [Related]
20. Survival Outcomes of Men with Lymph Node-positive Prostate Cancer After Radical Prostatectomy: A Comparative Analysis of Different Postoperative Management Strategies.
Touijer KA; Karnes RJ; Passoni N; Sjoberg DD; Assel M; Fossati N; Gandaglia G; Eastham JA; Scardino PT; Vickers A; Cozzarini C; Montorsi F; Briganti A
Eur Urol; 2018 Jun; 73(6):890-896. PubMed ID: 29042125
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
